1. Home
  2. TYRA vs PRGS Comparison

TYRA vs PRGS Comparison

Compare TYRA & PRGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$35.08

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Progress Software Corporation (DE)

PRGS

Progress Software Corporation (DE)

HOLD

Current Price

$27.73

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYRA
PRGS
Founded
2018
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
TYRA
PRGS
Price
$35.08
$27.73
Analyst Decision
Strong Buy
Buy
Analyst Count
11
6
Target Price
$47.50
$49.50
AVG Volume (30 Days)
1.1M
1.2M
Earning Date
05-06-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.79
EPS
N/A
0.53
Revenue
N/A
$397,572,000.00
Revenue This Year
N/A
$3.70
Revenue Next Year
N/A
$1.08
P/E Ratio
N/A
$51.83
Revenue Growth
N/A
N/A
52 Week Low
$8.75
$23.82
52 Week High
$40.65
$65.50

Technical Indicators

Market Signals
Indicator
TYRA
PRGS
Relative Strength Index (RSI) 45.54 41.97
Support Level $33.81 $23.82
Resistance Level $39.90 $29.99
Average True Range (ATR) 1.97 1.33
MACD -0.11 0.18
Stochastic Oscillator 29.08 22.31

Price Performance

Historical Comparison
TYRA
PRGS

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About PRGS Progress Software Corporation (DE)

Progress Software Corp provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. The following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include the United States, Canada, EMEA, Latin America, and Asia Pacific.

Share on Social Networks: